First Manhattan’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

First Manhattan’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21,510	Closed	-$2.72M	–	1687
2022 Q2	$2.72M	Hold	21,510	–	–	0.01%	293
2022 Q1	$2.73M	Hold	21,510	–	–	0.01%	324
2021 Q4	$2.82M	Sell	21,510 -10,600	-33%	-$1.37M	0.01%	305
2021 Q3	$3.93M	Hold	32,110	–	–	0.01%	254
2021 Q2	$3.66M	Hold	32,110	–	–	0.01%	263
2021 Q1	$3.86M	Sell	32,110 -34,726	-52%	-$3.93M	0.02%	262
2020 Q4	$6.79M	Hold	66,836	–	–	0.03%	192
2020 Q3	$5.17M	Buy	66,836 +30,300	+83%	+$2.58M	0.03%	217
2020 Q2	$4.07M	Sell	36,536 -21,764	-37%	-$1.89M	0.02%	231
2020 Q1	$4.2M	Hold	58,300	–	–	0.03%	224
2019 Q4	$4.39M	Buy	+58,300	New	+$2.55M	0.02%	252

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

First Manhattan's KRTX Position: Q3 2022 in Review

First Manhattan sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2022, closing a stake of 21,510 shares — an estimated $2.72M sold.

First Manhattan first reported a position in KRTX in Q4 2019 and held it in 11 quarters. The position peaked at $6.79M in Q4 2020. 257 funds tracked by Wall St. Rank hold KRTX as of Q3 2022.

First Manhattan reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
First Manhattan sold 21,510 Karuna Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.72M.
First Manhattan first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
First Manhattan's Karuna Therapeutics, Inc. Common Stock position peaked at $6.79M in Q4 2020.
257 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2022.

Based on First Manhattan's 13F filing for Q3 2022, filed 14 Nov 2022.